ClinicalTrials.gg
CompletedNCT01263704Updated Apr 23, 2018Results posted

A Study of MabThera/Rituxan (Rituximab) in Combination With Fludarabine And Cyclophosphamide as Primary Therapy in Elderly Patients With Chronic Lymphocytic Leukemia

A Phase 2 interventional study of Cyclophosphamide and Fludarabine in Lymphocytic Leukemia, Chronic, sponsored by Hoffmann-La Roche. Completed at 12 sites in Israel. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2018-04-23.

Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
42
Allocation
Non-randomized
Ages
65 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 155 studies testing cyclophosphamide in Leukemia, Lymphocytic, Chronic, B-Cell — 3 open to participants now, 11 under way, none of them phase 3. Cyclophosphamide · Leukemia, Lymphocytic, Chronic, B-Cell.

Enrollment
79th of 145
42 · median 49
Started
2011
with 7 others
Phase 2
100 of 155
1 open now
Registered
110th of 155
by date
Lead sponsor
7 of 155
Hoffmann-La Roche

Among the 155 studies testing cyclophosphamide in Leukemia, Lymphocytic, Chronic, B-Cell, this one is the 79th largest by enrollment of the 145 interventional ones that give a count, is one of 8 that started in 2011, is one of 100 in phase 2, and was the 110th registered.

Leukemia, Lymphocytic, Chronic, B-Cell

2,036 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 236 are open to participants now.

Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →

Open to participants now

3 of the 155 studies testing cyclophosphamide in Leukemia, Lymphocytic, Chronic, B-Cell are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About cyclophosphamide

Cyclophosphamide: first FDA approval 1959 (CYTOXAN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 187 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 150 (80%) set no upper age limit and 15 (8%) stop at 75 or younger; 17 take children under 18; 12 take healthy volunteers.

This study: 65 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 155 studies testing cyclophosphamide in Leukemia, Lymphocytic, Chronic, B-Cell, or all of them as a file.
02

Study summary

This single arm, open-label study will assess the safety and efficacy of low dose fludarabine and cyclophosphamide in combination with standard dose MabThera/Rituxan (rituximab) as primary therapy in elderly patients (>/= 65 years) with chronic lymphocytic leukemia. Patients will receive six 28-day cycles of treatment with Mabthera/Rituxan (375 mg/m2 intravenously [iv] Day 0 of cycle 1, 500 mg/m2 iv Day 1 of cycles 2-6), fludarabine (12.5 mg/m2/d iv Days 1-3, cycles 1-6) and cyclophosphamide (150 mg/m2/d iv Days 1-3, cycles 1-6). Anticipated time on study treatment is 6 months, with a 30-month follow-up period.

03

Conditions studied

  • Lymphocytic Leukemia, Chronic
04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients, >/= 65 years of age
  • Previously untreated B-cell chronic lymphocytic leukemia (CLL)
  • Binet stage C or active Binet stage A and B disease

Exclusion criteria

Exclusion Criteria:

  • Prior treatment for CLL
  • CLL with transformation (Richter's syndrome)
  • Suspected or known central nervous system (CNS) involvement of CLL
  • Impaired renal or hepatic function
  • (HIV) positivity, active /C or Hepatitis B Virus (HBV) surface antigen positive, or any active or uncontrolled infections
  • Patients with anti-HBV core antibodies (past infection with HBV) but who are negative for Hepatitis B Virus Surface Antigen (HBVsAg) (either anti-HBS Ab positive or negative) and are positive for HBV- Deoxyribonucleic acid (DNA) by Polymerase chain reaction (PCR) analysis
  • Concomitant diseases requiring chronic administration
  • Active second within the 2 years prior to study (except for non-melanoma skin cancer and in situ cervix or breast or prostate carcinoma)
  • (ECOG) performance status >/= 3
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
42 participants (actual)

Study arms

  • Experimental
    Rituximab plus Fludarabine and Cyclophosphamide

    Elderly participants with chronic lymphocytic leukemia (CLL) will receive combination treatment with low-dose fludarabine and cyclophosphamide combined with standard-dose of rituximab for 6 months. Treatment is followed by a follow up period of 36 months.

    Drug: Cyclophosphamide · Drug: Fludarabine · Drug: Rituximab

Interventions

  • 150 milligrams per square meter (mg/m\^2) intravenously (IV) on Days 1-3 of each 28-day cycle for 6 cycles

  • 12.5 mg/m\^2 IV on Days 1-3 of every 28-day cycle for 6 cycles

  • 375 mg/m\^2 IV Day 0 of Cycle 1, 500 mg/m\^2 IV Day 1 of Cycles 2-6. Each cycle was 28 days.

    Also known as: MabThera/Rituxan

06

What researchers measure

Primary outcomes

  1. Overall Response Rate

    Overall response rate was defined as the percentage of participants with a complete response (CR) or a partial response (PR) according to National Cancer Institute - Working Group \[NCI-WG\] guidelines. CR: no clonal B lymphocytes in peripheral blood, no significant lymphadenopathy, liver and spleen normal size, no disease symptoms, blood counts: absolute neutrophil count (ANC) \>1,500/microliter (mcL), platelets \> 100,000/mcL, hemoglobin \> 11.0 grams/deciliter (g/dL), normocellular bone marrow. PR: \>/= 50% decrease in clonal B lymphocyte count, \>/= 50% reduction in lymphadenopathy, \>/= 50% reduction of liver or spleen enlargement and ANC \>1,500/mcL, platelets \> 100,000/mcL, hemoglobin \> 11.0 g/dL OR \>/= 50% increase in ANC, platelets or hemoglobin.

    Time frame: Up to 42 months

Secondary outcomes

  1. Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

    An AE is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. Preexisting conditions which worsen during a study are also considered as adverse events. An SAE is any experience that suggests a significant hazard, contraindication, side effect, or precaution, and fulfills any of the following criteria: fatal (resulted in death), life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, was medically significant or required intervention to prevent any of the other outcomes listed here.

    Time frame: Up to 53 months

  2. Percentage of Participants With Neutropenic Fever, Infection, >/= Grade 3 Drug-Related Neutropenia, >/= Grade 3 Drug-Related Thrombocytopenia, Hospitalizations

    Time frame: Up to 53 months

  3. Hospitalization Days

    Time frame: Up to 53 months

  4. Progression-free Survival (PFS)

    PFS was defined as the interval from the first study drug treatment day to the first sign of disease progression according to NCI-WG guidelines. Progressive disease (PD): Any new lesion, any disease symptoms, \>/=50% increase in lymphadenopathy, splenomegaly, hepatomegaly, \>/= 50% increase in the number of circulating clonal B lymphocytes, decrease of hemoglobin levels by \> 2.0 g/dL, \>/= 50% decrease of platelet counts, increase of lymphocytes in bone marrow to more than 30% from normal.

    Time frame: Up to 53 months

  5. Quality of Life (QoL): Functional Assessment of Chronic Illness Therapy Fatigue (FACIT-F) Questionnaire

    The FACIT-F questionnaire consists of 13 questions with a total score range of 0 to 52 with 0 indicating a better outcome and 52 indicating a worse outcome.

    Time frame: [Visit 1 (Screening, Week 0), at Visits 11 (Week 45) and 14 (Week 80) and at the end of the study (Month 42)]

07

Results

Posted Apr 23, 2018

Participant flow

Participant flow — Overall Study
MilestoneRituximab Plus Fludarabine and Cyclophosphamide
Started42
Completed13
Not completed29
Withdrew: Progressive disease18
Withdrew: Adverse event3
Withdrew: Death2
Withdrew: Patient withdrew consent2
Withdrew: Eligibility criteria not fulfilled1
Withdrew: Lost to follow-up1
Withdrew: Colon metastases1
Withdrew: Principal investigator (pi) decision1

Outcome measures

PrimaryOverall Response Rate

Overall response rate was defined as the percentage of participants with a complete response (CR) or a partial response (PR) according to National Cancer Institute - Working Group \[NCI-WG\] guidelines. CR: no clonal B lymphocytes in peripheral blood, no significant lymphadenopathy, liver and spleen normal size, no disease symptoms, blood counts: absolute neutrophil count (ANC) \>1,500/microliter (mcL), platelets \> 100,000/mcL, hemoglobin \> 11.0 grams/deciliter (g/dL), normocellular bone marrow. PR: \>/= 50% decrease in clonal B lymphocyte count, \>/= 50% reduction in lymphadenopathy, \>/= 50% reduction of liver or spleen enlargement and ANC \>1,500/mcL, platelets \> 100,000/mcL, hemoglobin \> 11.0 g/dL OR \>/= 50% increase in ANC, platelets or hemoglobin.

Time frame:
Up to 42 months
Reported as:
Number · percentage of participants
Overall Response Rate
percentage of participantsRituximab Plus Fludarabine and Cyclophosphamide
Overall Response Rate67.5 (50.9 to 81.4)
SecondaryPercentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

An AE is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. Preexisting conditions which worsen during a study are also considered as adverse events. An SAE is any experience that suggests a significant hazard, contraindication, side effect, or precaution, and fulfills any of the following criteria: fatal (resulted in death), life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, was medically significant or required intervention to prevent any of the other outcomes listed here.

Time frame:
Up to 53 months
Reported as:
Number · percentage of participants
Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
percentage of participantsRituximab Plus Fludarabine and Cyclophosphamide
AEs97.6
SAEs45.2
SecondaryPercentage of Participants With Neutropenic Fever, Infection, >/= Grade 3 Drug-Related Neutropenia, >/= Grade 3 Drug-Related Thrombocytopenia, Hospitalizations
Time frame:
Up to 53 months
Reported as:
Number · percentage of participants
Percentage of Participants With Neutropenic Fever, Infection, >/= Grade 3 Drug-Related Neutropenia, >/= Grade 3 Drug-Related Thrombocytopenia, Hospitalizations
percentage of participantsRituximab Plus Fludarabine and Cyclophosphamide
Infection47.6
Neutropenic fever14.3
≥ Grade 3 drug-related neutropenia47.6
≥ Grade 3 drug-related thrombocytopenia11.9
Hospitalization19.1
SecondaryHospitalization Days
Time frame:
Up to 53 months
Reported as:
Median · days
Hospitalization Days
daysRituximab Plus Fludarabine and Cyclophosphamide
Hospitalization Days8 (2 to 13)
SecondaryProgression-free Survival (PFS)

PFS was defined as the interval from the first study drug treatment day to the first sign of disease progression according to NCI-WG guidelines. Progressive disease (PD): Any new lesion, any disease symptoms, \>/=50% increase in lymphadenopathy, splenomegaly, hepatomegaly, \>/= 50% increase in the number of circulating clonal B lymphocytes, decrease of hemoglobin levels by \> 2.0 g/dL, \>/= 50% decrease of platelet counts, increase of lymphocytes in bone marrow to more than 30% from normal.

Time frame:
Up to 53 months
Reported as:
Median · months
Progression-free Survival (PFS)
monthsRituximab Plus Fludarabine and Cyclophosphamide
Progression-free Survival (PFS)36.1 (27.3 to 48.1)
SecondaryQuality of Life (QoL): Functional Assessment of Chronic Illness Therapy Fatigue (FACIT-F) Questionnaire

The FACIT-F questionnaire consists of 13 questions with a total score range of 0 to 52 with 0 indicating a better outcome and 52 indicating a worse outcome.

Time frame:
[Visit 1 (Screening, Week 0), at Visits 11 (Week 45) and 14 (Week 80) and at the end of the study (Month 42)]
Reported as:
Mean · score on a scale
Quality of Life (QoL): Functional Assessment of Chronic Illness Therapy Fatigue (FACIT-F) Questionnaire
score on a scaleRituximab Plus Fludarabine and Cyclophosphamide
Visit 1 (Screening, Week 0)36.1 ± 11.1
Visit 11 (Week 45)39.4 ± 9.2
Visit 14 (Week 80)40.2 ± 10.1
End of the Study (Month 42)47.0 ± 1.0

Adverse events

Collected over Up to 53 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Rituximab Plus Fludarabine and Cyclophosphamide2/42 (4.8%)19/42 (45.2%)41/42 (97.6%)
Most frequent serious events
Showing 10 of 21
Most frequent serious events
EventRituximab Plus Fludarabine and Cyclophosphamide
Febrile neutropeniaBlood and lymphatic system disorders6/42
PyrexiaGeneral disorders3/42
PneumoniaInfections and infestations3/42
LeukopeniaBlood and lymphatic system disorders1/42
ThrombocytopeniaBlood and lymphatic system disorders1/42
Diabetes mellitusEndocrine disorders1/42
Pancreatitis acuteGastrointestinal disorders1/42
ChillsGeneral disorders1/42
Herpes zosterInfections and infestations1/42
Pneumonia bacterialInfections and infestations1/42
Most frequent other events
Showing 10 of 22
Most frequent other events
EventRituximab Plus Fludarabine and Cyclophosphamide
NeutropeniaBlood and lymphatic system disorders22/42
AnemiaBlood and lymphatic system disorders14/42
ThrombocytopeniaBlood and lymphatic system disorders10/42
CoughRespiratory, thoracic and mediastinal disorders10/42
AstheniaGeneral disorders8/42
ConstipationGastrointestinal disorders7/42
DiarrheaGastrointestinal disorders7/42
NauseaGastrointestinal disorders7/42
RashSkin and subcutaneous tissue disorders6/42
Infusion related reactionGeneral disorders5/42

Baseline characteristics

Intent-to-Treat (ITT) population included all enrolled participants.

Age, Continuous
Age, Continuous(years)Rituximab Plus Fludarabine and Cyclophosphamide
Mean72.9 ± 5.0
Sex: Female, Male
Sex: Female, Male(Participants)Rituximab Plus Fludarabine and Cyclophosphamide
Female13
Male29
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)Rituximab Plus Fludarabine and Cyclophosphamide
08

Study locations

12 sites
  • Haemek Medical Center; Hematology Department
    Afula, 18101, Israel
  • Soroka Medical Center; Hematology Deptartment
    Beer Sheva, 8410101, Israel
  • Rambam Medical Center; Heamatology & Bone Marrow Transplantation
    Haifa, 3109601, Israel
  • Bnei-Zion Medical Center; Hematology Dept
    Haifa, 3339419, Israel
  • Shaare Zedek Medical Center; Hematology Dept.
    Jerusalem, 9103102, Israel
  • Hadassah Ein Karem Hospital; Haematology
    Jerusalem, 9112001, Israel
  • Meir Medical Center; Internal Dept A
    Kfar Saba, 44281, Israel
  • Western Galilee Hospital - Nahariya
    Nahariya, 22100, Israel
  • Beilinson Medical Center; Haematology
    Petach Tikva, 49100, Israel
  • Kaplan Medical Center
    Rehovot, 7661041, Israel
  • ASSAF Harofe; Department of Hematology
    Rishon Lezion, 70300, Israel
  • Ichilov Sourasky Medical Center; Heamatology
    Tel Aviv, 6423906, Israel
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2011 to primary completion in Apr 2017, 68 months.

Results were first posted in Apr 2018, 1 year after primary completion.

Of 41 industry-sponsored phase 2 interventional studies under Leukemia, Lymphocytic, Chronic, B-Cell, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 87. This study's 68 months is above that.

Counting every sponsor, half of 249 studies reached it within 73 months; a quarter within 41 and three quarters within 114.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 17, 2010
First posted
Dec 21, 2010
StartActual
Jul 17, 2011
Primary completionActual
Apr 3, 2017
CompletionActual
Apr 3, 2017
Results first posted
Apr 23, 2018
Last update
Apr 23, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 23, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01263704
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Dec 21, 2010
Start date
Jul 17, 2011
Primary completion
Apr 3, 2017
Completion
Apr 3, 2017
Results posted
Apr 23, 2018
Last update
Apr 23, 2018

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Cyclophosphamide · Fludarabine · Rituximab

Start the discussion